Comment from Chronic Care Policy Alliance

Summary: The Chronic Care Policy Alliance (CCPA), a national coalition of patient advocacy organizations, opposes adding the nominated peptide substances to the Section 503A Bulks List. They argue that these substances have not undergone necessary FDA premarket review for safety and effectiveness and that compounding should remain a limited exception rather than a routine pathway for unreviewed therapies.